argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
Rhea-AI Summary
argenx (Euronext & Nasdaq: ARGX) will report its first quarter 2026 financial results and host a business update on May 7, 2026 at 2:30 PM CET / 8:30 AM ET. The company will hold a conference call and audio webcast for investors and analysts.
A live webcast is available at the Investors section of argenx.com/investors and a replay will remain accessible for approximately one year. Dial-in access numbers and access code 3810049 are provided; participants are asked to dial in 15 minutes early.
Positive
- None.
Negative
- None.
News Market Reaction – ARGX
In the Apr 30 session, ARGX gained 0.73%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Earnings date notice | Neutral | +0.2% | Scheduled full-year 2025 results call with webcast and replay details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior 'earnings date' scheduling news led to a very small move of about 0.23%, indicating historically muted reactions to this type of announcement.
Recent news for ARGX has highlighted strong financial performance and advancing neuromuscular programs. On Feb 26, 2026, full-year 2025 results showed multi‑billion product net sales and first-time operating profitability, alongside positive Phase 3 ADAPT OCULUS data. Earlier, on Jan 12, 2026, the company previewed 2025 net sales and laid out Vision 2030 priorities. The current earnings date announcement for Q1 2026 follows the same pattern of pre-scheduling detailed business updates via webcast.
AI-generated analysis. How Rhea-AI works. Not financial advice.
April 30, 2026
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 7, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2026 financial results and provide a business update.
A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.
Dial-in numbers:
Belgium 32 800 50 201
France 33 800 943355
Netherlands 31 20 795 1090
United Kingdom 44 800 358 0970
United States 1 888 415 4250
Japan 81 3 4578 9081
Switzerland 41 43 210 11 32
Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
